130 related articles for article (PubMed ID: 37058479)
1. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.
van Doesum JA; Salmanton-García J; Marchesi F; Di Blasi R; Falces-Romero I; Cabirta A; Farina F; Besson C; Weinbergerová B; Van Praet J; Schönlein M; López-García A; Lamure S; Guidetti A; De Ramón-Sánchez C; Batinić J; Gavriilaki E; Tragiannidis A; Tisi MC; Plantefeve G; Petzer V; Ormazabal-Vélez I; Marques de Almeida J; Marchetti M; Maertens J; Machado M; Kulasekararaj A; Hernández-Rivas JÁ; Gomes da Silva M; Fernández N; Espigado I; Drgoňa Ľ; Dragonetti G; Metafuni E; Calbacho M; Blennow O; Wolf D; van Anrooij B; Nunes Rodrigues R; Nordlander A; Martín-González JA; Liévin R; Jiménez M; Gräfe SK; García-Sanz R; Córdoba R; Rahimli L; van Meerten T; Cornely OA; Pagano L
Blood Adv; 2023 Jun; 7(11):2645-2655. PubMed ID: 37058479
[TBL] [Abstract][Full Text] [Related]
2. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy.
Xiao X; Chen P; Zhong Y; Luo X; Liu Y; Lu Y; Jin X; Qian W; Han W; Liang A; Liu H
Cancer Med; 2023 Nov; 12(22):20838-20846. PubMed ID: 37962082
[TBL] [Abstract][Full Text] [Related]
4. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
[TBL] [Abstract][Full Text] [Related]
5. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.
McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090
[TBL] [Abstract][Full Text] [Related]
7. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
Wu X; Wang L; Shen L; He L; Tang K
J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
[TBL] [Abstract][Full Text] [Related]
8. Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
Tan JY; Wee LE; Tan YH; Conceicao EP; Lim FWI; Chen Y; Than H; Quek JKS; Nagarajan C; Goh YT; Hwang WYK; Phua GC; Chung SJ; Tan TT; Linn YC; Ho AYL; Tan BH
Transpl Infect Dis; 2023 Jun; 25(3):e14024. PubMed ID: 36715661
[TBL] [Abstract][Full Text] [Related]
9. Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.
Dahiya S; Luetkens T; Lutfi F; Avila S; Iraguha T; Margiotta P; Hankey KG; Lesho P; Law JY; Lee ST; Baddley J; Kocoglu M; Yared JA; Hardy NM; Rapoport AP; Atanackovic D
Blood Adv; 2022 Jan; 6(2):686-689. PubMed ID: 34941995
[No Abstract] [Full Text] [Related]
10. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy.
Lee D; Jordan AI; Menges MA; Lazaryan A; Nishihori T; Gaballa SR; Shah BD; Pinilla-Ibarz J; Baluch A; Klinkova OV; Chavez JC; Jain MD; Locke FL
Transplant Cell Ther; 2023 Apr; 29(4):277.e1-277.e9. PubMed ID: 35970303
[TBL] [Abstract][Full Text] [Related]
11. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
13. B-cell malignancies and COVID-19: a narrative review.
Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F;
Clin Microbiol Infect; 2023 Mar; 29(3):332-337. PubMed ID: 36336236
[TBL] [Abstract][Full Text] [Related]
14. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
15. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski K; Perez A; Iacoboni G; Penack O; Bücklein V; Jentzsch L; Mougiakakos D; Johnson G; Arciola B; Carpio C; Blumenberg V; Hoster E; Bullinger L; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Barba P; Jain MD; Subklewe M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580927
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.
Pagano L; Salmanton-García J; Marchesi F; Blennow O; Gomes da Silva M; Glenthøj A; van Doesum J; Bilgin YM; López-García A; Itri F; Nunes Rodrigues R; Weinbergerová B; Farina F; Dragonetti G; Berg Venemyr C; van Praet J; Jaksic O; Valković T; Falces-Romero I; Martín-Pérez S; Jiménez M; Dávila-Valls J; Schönlein M; Ammatuna E; Meers S; Delia M; Stojanoski Z; Nordlander A; Lahmer T; Imre Pinczés L; Buquicchio C; Piukovics K; Ormazabal-Vélez I; Fracchiolla N; Samarkos M; Méndez GA; Hernández-Rivas JÁ; Espigado I; Cernan M; Petzer V; Lamure S; di Blasi R; Marques de Almedia J; Dargenio M; Biernat MM; Sciumè M; de Ramón C; de Jonge N; Batinić J; Aujayeb A; Marchetti M; Fouquet G; Fernández N; Zambrotta G; Sacchi MV; Guidetti A; Demirkan F; Prezioso L; Ráčil Z; Nucci M; Mladenović M; Liévin R; Hanáková M; Gräfe S; Sili U; Machado M; Cattaneo C; Adžić-Vukičević T; Verga L; Labrador J; Rahimli L; Bonanni M; Passamonti F; Pagliuca A; Corradini P; Hoenigl M; Koehler P; Busca A; Cornely OA
Blood; 2022 Dec; 140(26):2773-2787. PubMed ID: 36126318
[TBL] [Abstract][Full Text] [Related]
17. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
[TBL] [Abstract][Full Text] [Related]
18. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
[TBL] [Abstract][Full Text] [Related]
20. On a collision course: SARS-CoV-2 variants and CAR T cells.
Auletta JJ
Blood Adv; 2023 Jun; 7(11):2643-2644. PubMed ID: 37310762
[No Abstract] [Full Text] [Related]
[Next] [New Search]
